Lippincott®18新利体育客户端®Wolters Kluwer标志

新药物适应症- 2021年9月

去铁酮

Ferriprox

制药公司：基耶西美国

新的表格

口头的解决方案:80毫克/毫升

平板：每日一次给药1000毫克；b.i.d.剂量为1000 mg

适应症和剂量

地中海贫血综合征患者输血铁超负荷的治疗

8岁及以上的成人和儿童：开始时，25毫克/公斤片剂或口服溶液口服每日一次，或25毫克/公斤片剂口服每日一次，总共75毫克/公斤/天。可根据患者反应和治疗目标滴定至99mg /kg/天的最大剂量。剂量应接近500mg (1000 -mg片剂的一半)，250mg (500-mg片剂的一半)或2.5 mL口服溶液。

3岁及以上儿童:最初，每天口服25 mg/kg溶液，总剂量为75 mg/kg。可根据患者反应和治疗目标滴定至99 mg/kg/天的最大剂量。圆形剂量，精确至2.5毫升口服溶液。

镰状细胞病或其他贫血患者输血铁超载的治疗

8岁及以上的成人和儿童：开始时，25毫克/公斤片剂或口服溶液口服每日一次，或25毫克/公斤片剂口服每日一次，总共75毫克/公斤/天。可根据患者反应和治疗目标滴定至99mg /kg/天的最大剂量。剂量应接近500mg (1000 -mg片剂的一半)，250mg (500-mg片剂的一半)或2.5 mL口服溶液。

3岁及以上儿童:最初，每天口服25 mg/kg溶液，总剂量为75 mg/kg。可根据患者反应和治疗目标滴定至99 mg/kg/天的最大剂量。圆形剂量，精确至2.5毫升口服溶液。

调整剂量（两种适应症）：为了最大限度地减少启动治疗时的GI损伤，可以从45mg / kg /天开始，每周增加15毫克/千克/天。如果血清铁蛋白水平始终低于500 mcg / L，则考虑临时治疗中断。对于少于1,500 / mm3.，立即中断治疗并监测直至康复；除非潜在的好处大于风险，否则不要再次挑战。对于小于500/mm的ANC3.考虑住院和其他临床适当的管理；除非潜在利益大于风险，否则不要继续。

发布日期：2021年9月

新利18娱乐网址是多少护理药物手册

©2021 Wolters Kluwer

泊沙康唑

泊沙康唑

制药公司：默克-夏普和多梅公司

新适应症和剂量

侵袭性曲霉病的治疗

13至17岁的成人和儿童：第一天每天一次口服300毫克延迟释放片，然后每天一次口服300毫克。或者，第一天每天静脉注射300毫克，然后每天注射300毫克，持续6至12周。可在IV和延迟释放片剂之间切换；在配方之间切换时不需要加载剂量。

发布日期：2021年9月

新利18娱乐网址是多少护理药物手册

©2021 Wolters Kluwer

secnidazole

Solosec

制药公司：卢平制药

新适应症和剂量

治疗滴虫病

成人：一次单剂量2 g PO。同时用同样的剂量治疗性伴侣。

发布日期：2021年9月

新利18娱乐网址是多少护理药物手册

©2021 Wolters Kluwer

sugammadex

新娘

制药公司：默克-夏普和多梅公司

新适应症和剂量

罗库溴铵和维库溴铵对手术患者神经肌肉阻滞的逆转作用

2岁及以上儿童（常规逆转罗库溴铵和维库溴铵诱导的神经肌肉阻滞）：给药的基本剂量和时间取决于抽搐反应和自发恢复的程度。如果抽搐反应的恢复达到一到两次强直后计数，并且对四次训练（TOF）刺激没有抽搐反应，则在10秒内给予4 mg/kg静脉推注。如果在TOF刺激下，自发恢复达到第二次抽搐的再现，则在10秒内给予2mg/kg静脉推注。

警觉的：仅罗库溴铵诱导的神经肌肉阻滞的即时逆转尚未在儿童中进行研究。

发布日期：2021年9月

新利18娱乐网址是多少护理药物手册

©2021 Wolters Kluwer

新药适应症档案

新药物适应症- 2021年9月
deferiproneFerriproxPharmaceutical company:Chiesi USA新的可用配方口服液：80毫克/毫升片剂：每天一次给药1000毫克；地中海贫血综合征患者以及8岁及以上儿童的输血铁超负荷的b.i.d.剂量指导和剂量治疗：最初，每天服用25 mg/kg片剂或口服溶液，或每天服用25 mg/kg片剂，总剂量为75 mg/kg。可根据患者反应和治疗目标滴定至99 mg/kg/天的最大剂量。圆形剂量，精确至500毫克（1000毫克片剂的一半）、250毫克（500毫克片剂的一半）或2.5毫升口服溶液。3岁及3岁以上儿童：最初，每天口服25 mg/kg溶液，总剂量为75 mg/kg。可根据患者反应和治疗目标滴定至99 mg/kg/天的最大剂量。圆形剂量，精确至2.5毫升口服溶液。镰状细胞病或其他贫血患者以及8岁及以上儿童的输血铁超负荷治疗：最初，每天服用25 mg/kg片剂或口服溶液，或每天服用25 mg/kg片剂，总剂量为75 mg/kg。可根据患者反应和治疗目标滴定至99 mg/kg/天的最大剂量。圆形剂量，精确至500毫克（1000毫克片剂的一半）、250毫克（500毫克片剂的一半）或2.5毫升口服溶液。3岁及3岁以上儿童：最初，每天口服25 mg/kg溶液，总剂量为75 mg/kg。可根据患者反应和治疗目标滴定至99 mg/kg/天的最大剂量。圆形剂量，精确至2.5毫升口服溶液。调整a剂量（针对两种适应症）：为了在开始治疗时尽量减少胃肠道紊乱，可以从45 mg/kg/天开始，每周增加15 mg/kg/天。如果血清铁蛋白水平始终低于500微克/升，考虑暂时治疗中断。对于ANC小于1500/mm3的患者，立即中断治疗并监测直至康复；除非潜在的好处大于风险，否则不要再次挑战。对于ANC小于500 /mM3，考虑住院和其他临床适当的管理；除非潜在益处大于风险，否则不要恢复。发布日期：2021年9月《护理药物手册》©2021 Wolters Kluwerposaconzonoxafil制药公司：默克夏普&多曼新适应症和剂量侵袭性曲霉菌病治疗13至17岁的成人和儿童：每天一次服用300毫克延迟释放片，然后每日一次，每次300毫克。或者，第一天每天静脉注射300毫克，然后每天注射300毫克，持续6至12周。可在IV和延迟释放片剂之间切换；在配方之间切换时不需要加载剂量。发布日期：2021年9月《护理药物手册》©2021 Wolters Kluwersecnidazole SoloseCharmeraceutical company:Lupin Pharmaceuticals滴虫病的新适应症和剂量治疗结果：单次剂量2 g PO。同时以相同剂量治疗性伴侣。发布日期：2021年9月《护理药物手册》©2021 Wolters Kluwersugammadexbridion制药公司：默克夏普公司和多西奈公司对接受手术的2岁及以上儿童使用罗库溴铵和维库溴铵诱导的神经肌肉阻滞的适应症和剂量管理（罗库溴铵和维库溴铵诱导的神经肌肉阻滞的常规逆转）：根据抽搐反应和自发恢复程度给药的基本剂量和时间。如果抽搐反应的恢复达到强直后一到两次计数，并且对四次训练（TOF）没有抽搐反应，则在10秒内给予4 mg/kg静脉推注刺激。如果在TOF刺激下，自发恢复达到第二次抽搐的再现，则在10秒钟内给予2mg/kg静脉推注。警告：在儿童中尚未研究仅罗库溴铵诱导的神经肌肉阻滞的立即逆转。发布日期：2021年9月《护理药物手册》©2021 Wolters Kluwer新利18娱乐网址是多少
新药适应症-2021年8月
非索罗定fumarateToviazPharmaceutical公司：PfizerNEW INDICATION＆DOSAGENeurogenic逼尿肌overactivityChildren 6岁及以上的重量超过35公斤：每天一次持续1周4毫克PO，然后增加至8mg一次daily.Children 6岁及以上的体重超过25千克，高达35公斤：每天一次4毫克PO。可以增加至8毫克，每天一次，如果needed.Adjust-A-剂量：在儿童体重超过25千克到35千克，推荐剂量为4mg每日;不推荐使用此药物如果EGFR是29毫升/分钟/1.73平方米。在儿童体重35公斤以上且EGFR是29毫升/分钟/1.73平方米，推荐剂量为4mg每日;不推荐使用此药物如果EGFR是小于15毫升/分钟/1.73平方米。如果同时给予儿童体重超过35公斤强CYP3A4抑制剂，最大剂量为4mg每日;在儿童体重超过25公斤，长达35个kg.CONTRAINDICATIONS和CAUTIONSAlert不建议合用：禁忌症过敏的托特罗定tartrate.Released八月2021Nursing药物手册©2021威科Kluwerglecaprevir-pibrentasvirMavyretPharmaceutical公司：艾伯维，Inc.NEW可用FORMOral新利18娱乐网址是多少粒料：50毫克glecaprevir和20mg pibrentasvirNEW INDICATION＆DOSAGEChronic丙型肝炎病毒（HCV）基因型1，2，3，4，5，或6感染治疗过的患者无肝硬化或代偿性肝硬化（Child-Pugh分级类A）儿童3岁及以上或体重至少45公斤：300毫克glecaprevir / 120毫克pibrentasvir PO每天一次持续8个weeks.Children 3岁及以上或重达30千克至少高于45千克：250毫克glecaprevir / 100毫克pibrentasvir PO一次每日8个weeks.Children 3岁及以上的体重20公斤至小于30公斤：200毫克glecaprevir / 80毫克pibrentasvir PO每天一次持续8个weeks.Children 3岁及以上的重量小于20 kg: 150 mg glecaprevir/60 mg pibrentasvir PO once daily for 8 weeks.HCV genotype 1 infection with or without compensated cirrhosis (Child-Pugh class A) in patients previously treated with an HCV NS5A inhibitor but without an NS3/4A protease inhibitor (PI)Children age 3 and older or weighing at least 45 kg: 300 mg glecaprevir/120 mg pibrentasvir PO once daily for 16 weeks.Children age 3 and older or weighing 30 kg to less than 45 kg: 250 mg glecaprevir/100 mg pibrentasvir PO once daily for 16 weeks.Children age 3 and older weighing 20 kg to less than 30 kg: 200 mg glecaprevir/80 mg pibrentasvir PO once daily for 16 weeks.Children age 3 and older weighing less than 20 kg: 150 mg glecaprevir/60 mg pibrentasvir PO once daily for 16 weeks.HCV genotype 1 infection with or without compensated cirrhosis (Child-Pugh class A) in patients previously treated with an NS3/4A PI without an NS5A inhibitorChildren age 3 and older or weighing at least 45 kg: 300 mg glecaprevir/120 mg pibrentasvir PO once daily for 12 weeks.Children age 3 and older or weighing 30 kg to less than 45 kg: 250 mg glecaprevir/100 mg pibrentasvir PO once daily for 12 weeks.Children age 3 and older weighing 20 kg to less than 30 kg: 200 mg glecaprevir/80 mg pibrentasvir PO once daily for 12 weeks.Children age 3 and older weighing less than 20 kg: 150 mg glecaprevir/60 mg pibrentasvir PO once daily for 12 weeks.HCV genotype 1, 2, 4, 5, or 6 infection without cirrhosis in patients who previously received regimens containing interferon, pegylated interferon, ribavirin, or sofosbuvir but without prior treatment with an HCV NS3/4A PI or NS5A inhibitorChildren age 3 and older or weighing at least 45 kg: 300 mg glecaprevir/120 mg pibrentasvir PO once daily for 8 weeks.Children age 3 and older or weighing 30 kg to less than 45 kg: 250 mg glecaprevir/100 mg pibrentasvir PO once daily for 8 weeks.Children age 3 and older weighing 20 kg to less than 30 kg: 200 mg glecaprevir/80 mg pibrentasvir PO once daily for 8 weeks.Children age 3 and older weighing less than 20 kg: 150 mg glecaprevir/60 mg pibrentasvir PO once daily for 8 weeks.HCV genotype 1, 2, 4, 5, or 6 infection with compensated cirrhosis (Child-Pugh class A) in patients who previously received regimens containing interferon, pegylated interferon, ribavirin, or sofosbuvir, but without prior treatment with an HCV NS3/4A PI or NS5A inhibitorChildren age 3 and older or weighing at least 45 kg: 300 mg glecaprevir/120 mg pibrentasvir PO once daily for 12 weeks.Children age 3 and older or weighing 30 kg to less than 45 kg: 250 mg glecaprevir/100 mg pibrentasvir PO once daily for 12 weeks.Children age 3 and older weighing 20 kg to less than 30 kg: 200 mg glecaprevir/80 mg pibrentasvir PO once daily for 12 weeks.Children age 3 and older weighing less than 20 kg: 150 mg glecaprevir/60 mg pibrentasvir PO once daily for 12 weeks.HCV genotype 3 infection without cirrhosis or with compensated cirrhosis (Child-Pugh class A) in patients who previously received regimens containing interferon, pegylated interferon, ribavirin, or sofosbuvir, but without prior treatment with an HCV NS3/4A PI or NS5A inhibitorChildren age 3 and older or weighing at least 45 kg: 300 mg glecaprevir/120 mg pibrentasvir PO once daily for 16 weeks.Children age 3 and older or weighing 30 kg to less than 45 kg: 250 mg glecaprevir/100 mg pibrentasvir PO once daily for 16 weeks.Children age 3 and older weighing 20 kg to less than 30 kg: 200 mg glecaprevir/80 mg pibrentasvir PO once daily for 16 weeks.Children age 3 and older weighing less than 20 kg: 150 mg glecaprevir/60 mg pibrentasvir PO once daily for 16 weeks.Released: August 2021Nursing Drug Handbook© 2021 Wolters KluwerozanimodZeposiaPharmaceutical company: Bristol Myers SquibbNEW INDICATION & DOSAGEModerate to severe active ulcerative colitisAdults: Initially, 0.23 mg PO once daily on days 1 to 4, then 0.46 mg PO once daily on days 5 to 7, then maintenance dose of 0.92 mg PO once daily.Released: August 2021Nursing Drug Handbook© 2021 Wolters KluwerposaconazoleNoxafilPharmaceutical company: Merck Sharp & Dohme Corp.NEW AVAILABLE FORMPowder for delayed-release oral suspension: 300 mgNEW INDICATION & DOSAGEPrevention of invasive Aspergillus and Candida infections in patients with a high-risk of immunocompromise until recovered from neutropenia or immunosuppressionIV infusionChildren ages 2 to less than 18: 6 mg/kg up to a maximum of 300-mg IV infusion b.i.d. on first day, then 6 mg/kg to a maximum of 300 mg once daily.Delayed-release oral suspensionChildren age 2 to less than 18 weighing 36 to 40 kg: 240 mg (8 mL) PO b.i.d on first day, then 240 mg once daily.Children age 2 to less than 18 weighing 26 to less than 36 kg: 210 mg (7 mL) PO b.i.d. on first day, then 210 mg once daily.Children age 2 to less than 18 weighing 21 to less than 26 kg: 180 (6 mL) mg PO b.i.d. on first day, then 180 mg once daily.Children age 2 to less than 18 weighing 17 to less than 21 kg: 150 mg (5 mL) PO b.i.d. on first day, then 150 mg once daily.Children age 2 to less than 18 weighing 12 to less than 17 kg: 120 mg (4 mL) PO b.i.d. on first day, then 120 mg once daily.Children age 2 to less than 18 weighing 10 to less than 12 kg: 90 mg (3 mL) PO b.i.d. on first day, then 90 mg once daily.Alert: Powder for delayed-release oral suspension is contraindicated in patients with known or suspected hereditary fructose intolerance.Released: August 2021Nursing Drug Handbook© 2021 Wolters Kluwerravulizumab-cwvzUltomirisPharmaceutical company: Alexion PharmaceuticalsNEW AVAILABLE FORMInjection: 300 mg/3 ml (100 mg/mL) and 1,100 mg/11 mL (100 mg/mL) single-dose vialsNEW INDICATION & DOSAGETreatment of paroxysmal nocturnal hemoglobinuriaChildren age 1 month and older weighing 100 kg or more: 3,000-mg IV infusion loading dose, followed in 2 weeks by maintenance dose of 3,600-mg IV infusion once every 8 weeks.Children age 1 month and older weighing 60 to less than 100 kg: 2,700-mg IV infusion loading dose, followed in 2 weeks by maintenance dose of 3,300-mg IV infusion once every 8 weeks.Children age 1 month and older weighing 40 to less than 60 kg: 2,400-mg IV infusion loading dose, followed in 2 weeks by maintenance dose of 3,000-mg IV infusion once every 8 weeks.Children age 1 month and older weighing 30 to less than 40 kg: 1,200-mg IV infusion loading dose, followed in 2 weeks by maintenance dose of 2,700-mg IV infusion once every 8 weeks.Children age 1 month and older weighing 20 to less than 30 kg: 900-mg IV infusion loading dose, followed in 2 weeks by maintenance dose of 2,100-mg IV infusion once every 8 weeks.Children age 1 month and older weighing 10 to less than 20 kg: 600-mg IV infusion loading dose, followed in 2 weeks by maintenance dose of 600-mg IV infusion once every 4 weeks.Children age 1 month and older weighing 5 to less than 10 kg: 600-mg IV infusion loading dose, followed in 2 weeks by maintenance dose of 300-mg IV infusion once every 4 weeks.Released: August 2021Nursing Drug Handbook© 2021 Wolters KluwerrimegepantNurtec ODTPharmaceutical company: Biohaven PharmaceuticalsNEW INDICATION & DOSAGEPrevention of episodic migraineAdults: 75 mg PO every other day.Released: August 2021Nursing Drug Handbook© 2021 Wolters KluwersecukinumabCosentyxPharmaceutical company: Novartis PharmaceuticalsNEW INDICATION & DOSAGEModerate to severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapyChildren age 6 and older weighing 50 kg or more: 150 mg subcut at weeks 0, 1, 2, 3, and 4; then 150 mg every 4 weeks thereafter.Children age 6 and older weighing less than 50 kg: 75 mg subcut at weeks 0, 1, 2, 3, and 4; then 75 mg every 4 weeks thereafter.Released: August 2021Nursing Drug Handbook© 2021 Wolters Kluwersofosbuvir–velpatasvirEpclusaPharmaceutical company: Gilead SciencesNEW AVAILABLE FORMOral pellets: 150 mg sofosbuvir and 37.5 mg velpatasvir; 200 mg sofosbuvir and 50 mg velpatasvir packetsNEW INDICATION & DOSAGEChronic hepatitis C virus genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh class A) or with decompensated cirrhosis (Child-Pugh class B or C) in combination with ribavirinChildren age 3 and older weighing at least 30 kg: 400 mg sofosbuvir and 100 mg velpatasvir PO once daily for 12 weeks. Refer to the manufacturer's instructions for ribavirin weight-based dosing.Children age 3 and older weighing 17 to less than 30 kg: 200 mg sofosbuvir and 50 mg velpatasvir PO once daily for 12 weeks. Refer to the manufacturer's instructions for ribavirin weight-based dosing.Children age 3 and older weighing less than 17 kg: 150 mg sofosbuvir and 37.5 mg velpatasvir PO once daily for 12 weeks. Refer to the manufacturer's instructions for ribavirin weight-based dosing.Released: August 2021Nursing Drug Handbook© 2021 Wolters KluweravapritinibAyvakitPharmaceutical company: Blueprint MedicinesNEW INDICATION & DOSAGEAdvanced systemic mastocytosisAdults: 200 mg PO once daily until disease progression or unacceptable toxicity occurs.Adjust-a-dose: Reduce starting dose to 50 mg PO once daily when giving with moderate CYP3A inhibitor. Recommended dose has not been established for patients with severe renal impairment, end-stage renal disease, or severe hepatic impairment. This drug is not recommended for patients with platelet counts less than 50 x 109/L. Refer to the manufacturer's instructions for toxicity-related dosage adjustments. Permanently discontinue drug if patient cannot tolerate 25 mg once daily.Released: August 2021Nursing Drug Handbook© 2021 Wolters KluwerdabigatranPradaxaPharmaceutical company: Boehringer IngelheimNEW INDICATION & DOSAGETreatment of venous thromboembolism (VTE) in children previously treated with parenteral anticoagulant for at least 5 daysChildren age 8 to less than 18 (capsules): Weight-based dose PO b.i.d. according to the manufacturer's instructions.Children age 3 months to less than 12 years (pellets): Weight-based dose PO b.i.d. according to the manufacturer's instructions.Adjust-a-dose: Avoid use in children with eGFR less than 50 mL/min/1.73 m2.To reduce the risk of recurrence of VTE in previously treated childrenChildren age 8 to less than 18 (capsules): Weight-based dose PO b.i.d. after previous treatment according to the manufacturer's instructions.Children age 3 months to less than 12 years (pellets): Weight-based dose PO b.i.d. after previous treatment according to the manufacturer's instructions.Adjust-a-dose: Avoid use in children with eGFR less than 50 mL/min/1.73 m2.Released: August 2021Nursing Drug Handbook© 2021 Wolters Kluwerelexacaftor–tezacaftor–ivacaftor and ivacaftorTrikaftaPharmaceutical company: Vertex PharmaceuticalsNEW AVAILABLE FORMTablets: 50 mg elexacaftor, 25 mg tezacaftor, and 37.5 mg ivacaftor (fixed-dose combination), copackaged with 75 mg ivacaftorNEW INDICATION & DOSAGECystic fibrosis in patients who have at least one F508del mutation in the CFTR geneChildren age 6 to less than 12 years weighing 30 kg or more: Two tablets (each containing 100 mg elexacaftor, 50 mg tezacaftor, and 75 mg ivacaftor) PO in the morning, followed by one 150-mg ivacaftor tablet in the evening about 12 hours later.Children age 6 to less than 12 years weighing less than 30 kg: Two tablets (each containing 50 mg elexacaftor, 25 mg tezacaftor, and 37.5 mg ivacaftor) PO in the morning, followed by one 75-mg ivacaftor tablet in the evening about 12 hours later.Adjust-a-dose: For patients with moderate hepatic impairment (Child-Pugh class B), two tablets (each containing elexacaftor, tezacaftor, and ivacaftor) PO in the morning on day 1, alternating with one tablet in the morning on day 2. No evening dose of ivacaftor should be taken. For patients currently receiving moderate and strong CYP3A inhibitors, refer to the manufacturer's instructions for dosage adjustments.Released: August 2021Nursing Drug Handbook© 2021 Wolters Kluwer
新药物适应症——2021年7月
dapagliflozinfarxigpharma公司:阿斯利康(astrazeneca)新适应症和剂量:降低有进展风险的慢性肾病患者eGFR持续下降、终末期肾病(ESRD)、CV死亡和心力衰竭住院的风险成人:10 mg PO，每日1次。调整剂量:当eGFR小于25ml /min/1.73 m2时，不推荐使用该药物;然而，患者可继续每日服用10mg PO，以降低eGFR下降、ESRD、CV死亡和心力衰竭住院的风险。禁忌症和注意事项本药物不推荐用于多囊肾病患者的慢性肾脏疾病的治疗，也不推荐用于目前或近期对肾脏疾病进行免疫抑制治疗的患者。发布:2021年7月护理药物手册©20新利18娱乐网址是多少21 Wolters Kluwerdiclofenac potassiumZipsorPharmaceutical company: Assertio Therapeutics, Inc.NEW INDICATION & DOSAGEMild to moderate acute pain (Zipsor)Adults and children age 12 and older: 25 mg PO q.i.d.Released: July 2021Nursing Drug Handbook© 2021 Wolters KluwernivolumabOpdivoPharmaceutical company: Bristol-Myers SquibbNEW INDICATION & DOSAGEAdjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapyAdults: 240-mg IV infusion every 2 weeks, or 480-mg IV infusion every 4 weeks, until disease progression or unacceptable toxicity occurs, or up to 1 year of treatment.Released: July 2021Nursing Drug Handbook© 2021 Wolters KluwerpembrolizumabKeytrudaPharmaceutical company: Merck Sharp & DohmeNEW INDICATION & DOSAGEFirst-line treatment in patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapyAdults: 200-mg IV infusion over 30 minutes every 3 weeks, or 400-mg IV infusion over 30 minutes every 6 weeks prior to trastuzumab and chemotherapy when given on the same day. Continue until disease progression or unacceptable toxicity occurs, or up to 24 months in those without disease progression.Monotherapy treatment in patients with locally recurrent advanced or metastatic gastric or GEJ adenocarcinoma whose tumors express PD-L1 as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and, if appropriate, HER2/neu-targeted therapyAdults: 200-mg IV infusion over 30 minutes every 3 weeks, or 400-mg IV infusion over 30 minutes every 6 weeks until disease progression or unacceptable toxicity occurs, or up to 24 months in those without disease progression.Released: July 2021Nursing Drug Handbook© 2021 Wolters KluwerspinosadNatrobaPharmaceutical company: ParaPRONEW INDICATION & DOSAGEScabies infestationAdults and children age 4 and older: Apply to skin to completely cover body from the neck to soles of feet. Patients with balding scalp should also apply to scalp, hairline, temples, and forehead. Allow skin to dry for 10 minutes before getting dressed. Leave on skin for 6 hours before showering or bathing.Released: July 2021Nursing Drug Handbook© 2021 Wolters Kluwer
新药物适应症- 2021年6月
alirocumabPraluentPharmaceutical公司：RegeneronNEW INDICATION＆DOSAGEAdjunct到其他LDL胆固醇（LDL-C）患者的纯合家族性高胆固醇降低LDL-CAdults -lowering疗法：150毫克subcut每2 weeks.Released：LillyNEW INDICATION：2021©2021威科KluwercetuximabErbituxPharmaceutical公司六月＆的头部和颈部的DOSAGESquamous细胞癌，作为单一药剂或与基于铂的治疗和fluorouracilAdults组合：500毫克/米2-IV输注在2小时内，每2周。氟尿嘧啶铂类治疗前完成输液1小时。继续治疗直至疾病进展或不可接受的毒性occurs.KRAS突变阴性（野生型），表皮生长因子受体（EGFR） - 表达，如通过结合FOLFIRI给出FDA批准的试验确定的转移性结直肠癌（伊立替康，5-FU，亚叶酸钙）化疗方案一线治疗或在病人谁是难治伊立替康的化疗，或在病人的一个代理人谁没有oxaliplatin-和伊立替康的化疗或谁给伊立替康组合是不耐irinotecanAdults：500毫克/米2-IV输注在2小时内，每2周。完成输注前1小时或伊立替康FOLFIRI。Continue therapy until disease progression or unacceptable toxicity occurs.Adjust-a-dose (for all indications): Refer to the manufacturer’s instructions for dosage adjustments for adverse reactions and treatment-related toxicities.Released: June 2021© 2021 Wolters Kluwerdaunorubicin and cytarabine liposomeVyxeosPharmaceutical company: Jazz PharmaceuticalsNEW INDICATION & DOSAGENewly diagnosed, therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changesChildren age 1 and older: A full course of therapy consists of one or two induction cycles followed by up to two consolidation cycles. For initial induction cycle, 44 mg/m2 daunorubicin/100 mg/m2 cytarabine IV infusion on days 1, 3, and 5. For patients who fail to achieve a response from first induction cycle, give a second induction cycle of 44 mg/m2 daunorubicin/100 mg/m2 cytarabine IV infusion on days 1 and 3. May give second induction cycle 2 to 5 weeks after first induction cycle if no unacceptable toxicity occurs with previous cycle.Give first consolidation cycle 5 to 8 weeks after start of the last induction. Recommended dose for each consolidation cycle is 29 mg/m2 daunorubicin/65 mg/m2 cytarabine IV infusion on days 1 and 3. Give second consolidation cycle 5 to 8 weeks after start of first consolidation cycle if no disease progression or unacceptable toxicity occurs.Adjust-a-dose: Refer to the manufacturer's instructions for toxicity-related dosage adjustments.Released: June 2021© 2021 Wolters KluwerdiazepamDiastatPharmaceutical company: Bausch HealthNEW INDICATION & DOSAGEAcute treatment of intermittent, stereotypic episodes of frequent seizure activity (seizure clusters, acute repetitive seizures) that are distinct from patient's usual seizure patternAdults and children age 12 and older: 0.2 mg/kg PR, rounding up to the nearest available dose form. A second dose may be given 4 to 12 hours later.Children ages 6 to 11: 0.3 mg/kg PR, rounding up to the nearest available dose form. A second dose may be given 4 to 12 hours later.Children ages 2 to 5: 0.5 mg/kg PR, rounding up to the nearest available dose form. A second dose may be given 4 to 12 hours later.Released: June 2021© 2021 Wolters KluwernivolumabOpdivoPharmaceutical company: Bristol-Myers SquibbNEW INDICATION & DOSAGEAdvanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapyAdults: 360-mg IV infusion every 3 weeks along with fluoropyrimidine- and platinum-containing chemotherapy every 3 weeks; or 240-mg IV infusion every 2 weeks along with fluoropyrimidine- and platinum-containing chemotherapy every 2 weeks until disease progression or unacceptable toxicity occurs, or up to 2 years in patients without disease progression.Adjust-a-dose: Refer to the manufacturer’s instructions for dosage adjustments for adverse reactions and treatment-related toxicities.Released: June 2021© 2021 Wolters KluwertreprostinilTyvasoPharmaceutical company: United Therapeutics Corp.NEW INDICATION & DOSAGEPulmonary arterial hypertension associated with interstitial lung disease in patients (WHO group 3) to improve exercise abilityAdults: Initially, 3 breaths (18 mcg) per treatment session q.i.d., approximately 4 hours apart. Increase dose by 3 breaths in 1- to 2-week intervals, as tolerated, to target maintenance dose of 9 breaths (54 mcg) q.i.d. If 3 breaths are not tolerated initially, decrease to 1 or 2 breaths and increase as tolerated.Released: June 2021© 2021 Wolters KluwervalsartanDiovanPharmaceutical company: NovartisNEW INDICATION & DOSAGEHypertensionChildren ages 1 to 16: Initially, 1 mg/kg PO daily (up to 40 mg total). Adjust according to patient response and tolerability, up to 4 mg/kg or 160 mg daily.Adjust-a-dose: Consider starting dose of 2 mg/kg in select cases when greater reduction of blood pressure is needed.Released: June 2021© 2021 Wolters Kluwer
新药适应症-2021年5月
阿达木霉素制药公司：Abbie新适应症和剂量，适用于体重40 kg或以上的5岁及以上严重活动性溃疡性结肠炎儿童：最初，第1天分次给药160 mg，1天给药或连续2天给药；然后在第8天和第15天服用80毫克，然后每隔一周服用80毫克，或从第4周（第29天）开始每周服用40毫克。5岁及以上的儿童体重从20公斤到40公斤以下：最初，在第1天服用80毫克，然后在第8天和第15天服用40毫克，从第4周（第29天）开始，每隔一周服用40毫克或每周服用20毫克的维持剂量.发布日期：2021年5月©2021年Wolters Kluweraxicabtageneyescartap制药公司：Kite Pharma新适应症和剂量管理器在两行或多行全身治疗后复发或难治性滤泡淋巴瘤成人：目标剂量为2×106 CAR阳性活T细胞/kg体重（或对于体重为100 kg或以上的患者，最多2×108 CAR阳性活T细胞）.调整剂量：有关毒性相关剂量调整，请参考制造商说明。发布日期：2021年5月©2021 Wolters Kluwermirabegoronmyrbetriq；Myrbetriq Granulespharmaceutice company:Astellas Pharma，Inc.新适应症和剂量剂神经源性逼尿肌过度活动3岁及以上儿童体重35 kg或以上（缓释片）：每天一次，每次25毫克。4至8周后，可增加至每天一次，最大剂量为50毫克。3岁及以上儿童体重为35公斤或以上（缓释颗粒）：最初，每天一次，每次6毫升（48毫克）。4至8周后，可增加至最大剂量，10毫升（80毫克）每日一次。3岁及以上儿童体重22至小于35千克（缓释颗粒）：最初，每日一次，每次服用4毫升（32毫克）。4至8周后，可增加至最大剂量，每天一次，每次服用8毫升（64毫克）。3岁及以上儿童体重11至小于22千克（缓释颗粒）：最初，每日一次，每次服用3毫升（24毫克）每日一次。4至8周后，可增加至最大剂量，6毫升（48毫克）每日一次。发布日期：2021年5月©2021年Wolters KluwerpembrolizumabKeytrudap制药公司：默克夏普公司。新适应症和剂量局部晚期或转移性食管癌或胃食管交界癌，不能进行外科切除或与铂和氟嘧啶联合进行确定性放化疗-基于化疗的药物：每3周静脉输注200mg或每6周静脉输注400mg，直到疾病进展或出现不可接受的毒性，或长达24个月。在化疗前给予彭布罗利珠单抗（当天给予）。局部晚期或转移性食管癌或胃食管交界癌，不能接受生存治疗对于表达PD-L1的鳞状细胞组织学肿瘤患者，经FDA批准的试验确定，在进行一次或多次系统治疗后，作为单一药物进行手术切除或最终化疗：每3周静脉输注200mg或每6周静脉输注400mg，直到疾病进展或出现不可接受的毒性发生，或长达24个月。发布日期：2021年5月©2021 Wolters-Kluwertocilizumabactempharmaceutical company:Genentech新适应症和剂量减缓系统性硬化相关间质性肺病患者肺功能下降率成人：每周一次，每次162毫克。发布日期：2021年5月©2021 Wolters-Kluwer

行政长官资源

新利18娱乐网址是多少护理资源

关于育儿中心新利18娱乐网址是多少18新利体育客户端

新利18体育手机客户端下载条款和条件- - - - - -隐私政策- - - - - -免责声明--v7.7.11

Baidu